Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
about
Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic ConceptsNeonatal outcome in pregnant patients with antiphospholipid syndrome.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeEfficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion.Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8.Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome.Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions.Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast.Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.Hypofibrinogenemia and the α-Fibrinogen Thr312Ala Polymorphism may be Risk Factors for Early Pregnancy Loss.Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study.Use of D-dimer measurement to guide anticoagulant treatment in recurrent pregnancy loss associated with antiphospholipid syndrome.Effectiveness of high-dose i.v. immunoglobulin therapy for pregnant women with aspirin-heparin-resistant secondary antiphospholipid syndrome.
P2860
Q26852537-502AE01E-16A6-43A7-A3C0-C96057FD7C79Q33418245-E3F7FA81-6CC6-4A42-AC5F-16893950CA03Q33731711-606C66DD-4F45-4D5E-9019-3540C3DB31E8Q33776843-09B01E1D-7AFA-440A-9B69-18E51F958312Q36421501-24E61488-9982-42C4-9B55-C0A293DBC852Q37087437-B812C1C4-CC3F-4FE2-9E29-85EA60A823FBQ38258585-BDB81457-B80D-4B8F-AB90-A720DAD9F2B6Q38726547-C0C79B67-411A-4BEA-8651-6C815264B94CQ38876334-E9A7B06E-20F3-4FEE-9A9B-51FF8F846D87Q38942818-232F86F9-6A33-464C-87B3-C370AD48C0F0Q38970808-8DF9FEBB-4DA0-4873-81FD-037C0087B267Q39264755-10E388FF-D349-4ED9-8C5C-57573A442F50Q41615471-C2D2C59F-43F4-43DD-AC39-76005A2FD4ECQ47176561-380F385D-99EB-4DB3-937D-4E797A5CE940Q47275497-804A7916-9B32-4A71-A36D-24F7F83A9A92Q48199427-5BC0F188-DA3F-4B96-AABA-3C5A9E09175CQ53691739-0B9276C6-E8EB-4C8C-BDD0-E83D132A9843
P2860
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
@en
type
label
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
@en
prefLabel
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
@en
P2093
P2860
P1476
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
@en
P2093
Guilherme R de Jesús
Gustavo Rodrigues
Nilson R de Jesús
P2860
P2888
P356
10.1007/S11926-013-0403-6
P50
P577
2014-02-01T00:00:00Z
P5875
P6179
1032392474